Mielecki Marcin, Lesyng Bogdan
Bioinformatics Laboratory, Mossakowski Medical Research Center, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland.
Curr Med Chem. 2016;23(10):954-82. doi: 10.2174/0929867323666160316123609.
Cinnamic acid belongs to phenolic-acid class of polyphenols, one of the most abundant plant secondary metabolites. These substances are widely studied because of plethora of their biological activities. In particular, their inhibition of protein kinases contributes to the pleiotropic effects in the cell. Protein kinases are essential in controlling cell signaling networks. Selective targeting of oncogenic protein kinases increases clinical anticancer efficacy. Cinnamic acid and related compounds have inspired researchers in the design of numerous synthetic and semisynthetic inhibitors of oncogenic protein kinases for the past three decades. Interest in cinnamoyl-scaffold-containing compounds revived in recent years, which was stimulated by modern drug design and discovery methodologies such as in vitro and in silico HTS. This review presents cinnamic acid derivatives and analogs for which direct inhibition of protein kinases was identified. We also summarize significance of the above protein kinase families - validated or promising targets for anticancer therapies. The inhibition mode may vary from ATP-competitive, through bisubstrate-competitive and mixedcompetitive, to non-competitive one. Kinase selectivity is often correlated with subtle chemical modifications, and may also be steered by an additional non-cinnamoyl fragment of the inhibitor. Specific cinnamic acid congeners may synergize their effects in the cell by a wider range of activities, like suppression of additional enzymes, e.g. deubiquitinases, influencing the same signaling pathways (e.g. JAK2/STAT). Cinnamic acid, due to its biological and physicochemical properties, provides nature-inspired ideas leading to novel inhibitors of oncogenic protein kinases and related enzymes, capable to target a variety of cancer cells.
肉桂酸属于多酚类中的酚酸类,是植物中最丰富的次生代谢产物之一。由于这些物质具有众多生物活性,因此受到广泛研究。特别是,它们对蛋白激酶的抑制作用导致了细胞中的多效性效应。蛋白激酶在控制细胞信号网络中至关重要。选择性靶向致癌蛋白激酶可提高临床抗癌疗效。在过去三十年中,肉桂酸及相关化合物激发了研究人员设计众多致癌蛋白激酶的合成和半合成抑制剂。近年来,受现代药物设计和发现方法(如体外和计算机辅助高通量筛选)的刺激,对含肉桂酰支架化合物的兴趣重新燃起。本综述介绍了已确定可直接抑制蛋白激酶的肉桂酸衍生物和类似物。我们还总结了上述蛋白激酶家族的重要性——它们是经过验证的或有前景的抗癌治疗靶点。抑制模式可能从ATP竞争性,经过双底物竞争性和混合竞争性,到非竞争性。激酶选择性通常与细微的化学修饰相关,也可能由抑制剂的额外非肉桂酰片段引导。特定的肉桂酸同系物可能通过更广泛的活性在细胞中协同发挥作用,例如抑制额外的酶,如去泛素酶,影响相同的信号通路(如JAK2/STAT)。由于其生物学和物理化学性质,肉桂酸提供了受自然启发的思路,可用于开发新型致癌蛋白激酶和相关酶的抑制剂,能够靶向多种癌细胞。